Xadpx
RankingsLogo

Eli Lilly and Company

Eli Lilly and Company is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Eli Lilly and Company is a pharmaceutical company that researches and manufactures treatments for diabetes, cancer, depression, heart disease, and other illnesses. It is known for being the first company to commercialize insulin, which treats diabetes. Other medicines include Trulicity and Mounjaro, which treat type 2 diabetes, and Verzenio, which treats cancer.

Ticker: LLY

Humankind Value: $1.0 T

Revenue: $28.1 B

Market Cap: $736.7 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Eli Lilly and Company is responsible for positive Humankind Value. Considerable positive value is associated with its contributions to Healthcare R&D ($930.1 B), Pharmaceuticals ($82.0 B), and Economic Value ($7.6 B). The value associated with Healthcare R&D and Pharmaceuticals is linked to an estimate of 19,000,000 additional years lived by people worldwide. The Humankind Value of this company can improve with reductions in Greenhouse Gases (-$1.8 B) and Air Pollution (-$230.1 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution impacts are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings